Use of domperidone has been associated with incidences of cardiac arrhythmias and cardiac arrest. Domperidone-containing products are no longer approved by the FDA, except for an investigational drug application. In response to reports that breastfeeding women may be using domperidone as an unapproved drug to increase milk production, the FDA has advised women not to use domperidone for this purpose.
- TRADE NAMES: Evoxin; Motilium (Johnson & Johnson)
- INDICATIONS: Investigational antiemetic, gastroesophageal reflux disease (GERD), nausea, vomiting
- CLASS: Antiemetic, Dopamine receptor antagonist
- HALF-LIFE: 7–8 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Bromocriptine, Darifenacin, Hydromorphone, Ketoconazole, Meptazinol, Oxybutynin, Tiotropium, Trospium
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of domperidone in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/20/2024
